Navigation Links
Researchers Develop Tool To Determine Individual Risk Of Prostate Cancer Overdiagnosis
Date:1/10/2014

SEATTLE, Jan. 10, 2014 /PRNewswire/ -- Studies have found that prostate cancer is overdiagnosed in up to 42 percent of cases, prompting men to receive unnecessary treatment that can cause devastating side effects, including impotence and incontinence.

Now, researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a personalized tool that can predict the likelihood of prostate cancer overdiagnosis. They announced their findings this week in the online issue of the Journal of the National Cancer Institute.

An overdiagnosed cancer is defined as one that would never cause symptoms or pose a risk to the patient, therefore not require treatment. Treatment of such cancers provides no benefit and can only cause harm.

The researchers created a nomogram, a graphical calculating device, that incorporates a patient's age, prostate-specific antigen (PSA) level and Gleason score - which grades prostate cancer tissue based on how it looks under a microscope - to determine the likelihood that screening-detected prostate cancer has been overdiagnosed.

The goal, said Roman Gulati, the study's lead author, is to provide patients and clinicians with a tool that can help them better determine personalized treatment options.

"Men with screen-detected prostate cancer are making decisions about treatment based on limited information about the chances that their cancer has been overdiagnosed," said Gulati, a statistical research associate in Fred Hutch's Public Health Sciences Division.

"We think this is a useful tool for patients and their providers because it helps to tailor knowledge of the risks and benefits of different treatment choices to their individual situations."

To develop the nomogram, the researchers created a virtual population model representing U.S. men aged 50 to 84 years from 1975 to 2005 and applied existing data on PSA levels, biopsy practices and cancer diagnosis patterns to learn about cancer progression in patients with and without screening. A virtual population was required since it was impossible to know how cancer may have progressed in real patients who were screened and subsequently treated.

The researchers, who also included University of Washington urologist John Gore, M.D., and biostatistician Lurdes Inoue, Ph.D., then overlaid screening and biopsy patterns on the model to determine when the men would have been diagnosed with and without screening, and which would have died of other causes.

They came up with a prediction model which estimates that the likelihood of overdiagnosis ranges from 2.9 to 88.1 percent depending on patient age, PSA level and Gleason score at diagnosis.

The biggest factor in overdiagnosis is age. While treatment may be warranted for a younger man with rapidly growing prostate cancer, its benefits are less clear for, say, a man in his 80s with a less aggressive form of the disease who is more likely to die from other causes before the cancer would become apparent.

While nomograms are common in prostate cancer research, the one developed by the Fred Hutch and UW researchers is the first to determine the likelihood of overdiagnosis on an individual level, said Ruth Etzioni, Ph.D., the paper's senior author.

"We're trying to help patients who are the most likely to be overdiagnosed to recognize it and not be afraid to be more conservative in their treatment," said Etzioni, a biostatistician, cancer modeler and member of the Hutch's Public Health Sciences Division.

Daniel Lin, M.D., a urologist at the University of Washington and an associate member of the Fred Hutch Public Health Sciences Division, said the nomogram could be a valuable tool for clinicians and patients.

"This nomogram will provide clinically relevant information for both the provider and patient on which to base practical decision-making for newly diagnosed prostate cancer," he said. "We fully realize that many men do not need immediate treatment for their cancer and can be safely placed on an active surveillance protocol, and this important research will further clarify those who may avoid treatment versus those men who may benefit from attempted curative therapy."

Etzioni said the next step is to develop an interface and test the nomogram in a pilot study tentatively planned for later this year. She believes the new tool has tremendous potential to help the more than 230,000 American men diagnosed with prostate cancer annually.

"The big buzzword in prostate cancer is shared and informed decision-making," she said. "We want to make sure men are better informed."

The National Cancer Institute and the Centers for Disease Control and Prevention supported this research.

Editor's note: For a related article about the research of Etzioni, Gulati and Gore, click here.

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit www.fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.

CONTACT:
Deborah Bach
206-667-2210
media@fredhutch.org


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rethinking Research Ethics: Carnegie Mellon and McGill Researchers Challenge Post-marketing Trial Practices
2. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
3. Researchers Evaluate Computer-based Treatment for People with Schizophrenia
4. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
5. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
6. Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer
7. Latest Breakthroughs and Treatments in Spinal Cord Injury Medicine Bring Top Clinicians and Researchers Together in Las Vegas
8. Researchers Set Record for Detecting Smallest Virus, Opening New Possibilities for Early Disease Detection
9. Researchers and Patient Advocates Honored with PhRMA Award
10. Leading Researchers Outline Principles for Conduct of Comparative Effectiveness Research
11. As Prescription Painkiller Overdoses Mount, Researchers Outline Effective Approaches to Curb Epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Medical information groups within the ... self-service capabilities to manage inquiries from external stakeholders ... New research from consulting leader Best Practices, LLC ... website portals where HCPs can sign on and ... many findings to emerge from the new study ...
(Date:2/24/2017)... -- Report analyzes the worldwide markets for Endodontic Supplies in ... US, Canada , Japan ... , Latin America , and Rest of ... 2015 through 2022. Also, a six-year historic analysis is provided ... primary and secondary research. Company profiles are primarily based on ...
(Date:2/24/2017)... -- Directors from Pharma To Market Pty Ltd and Ador Consulting Pte ... the founding of Pharma To Market Pte Ltd, based in ... to announce their expansion into Asia with ... The company are delighted to appoint Joelle Chia , former ... based entity. Joelle brings with her an extensive business ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim Jong-nam, ... nerve agents and the deadly use of chemical weapons. Many questions exist about the ... small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, ...
(Date:2/26/2017)... San Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Bay Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to ... San Mateo. Many Bay Area consumers look for home care close to home, and ...
(Date:2/26/2017)... Overland Park, KS (PRWEB) , ... ... ... launch of StaffBridge sets a new technology standard in staffing, scheduling, and ... to manage, monitor, and predict activity throughout the entire staffing process. StaffBridge ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... (PD) in persons with a specific LRRK2 mutation, according to a study released ... studies have provided evidence of a link between pesticides and incidence of sporadic ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... tooth replacement options at his office, Antoine Dental Center. Currently, patients can get ... Some restrictions may apply, but patients can learn more about these offers by ...
Breaking Medicine News(10 mins):